Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Mucopolysaccharidosis (MPS) Agents
Recombinant form of the human enzyme N-acetylgalactosamine 4-sulfatase; allows for the breakdown of certain glycosaminoglycans (GAGs) in cellular lysosomes; approved for enzyme replacement therapy of Mucopolysaccharidosis VI.
Naglazyme Intravenous Inj Sol: 1mg, 1mL
1 mg/kg IV infused over no less than 4 hours once per week. Administer at a rate of 6 mL/hour for the first hour. For patients receiving a 250 mL infusion: if the infusion is well tolerated, the rate can be increased to 80 mL/hour for the remaining 3 hours. For patients receiving a 100 mL infusion : if the infusion is well tolerated, the rate can be increased so that the remaining volume of the infusion is administered over 3 hours. If an infusion related reaction occurs, the infusion time can be extended to up to 20 hours.
No maximum dosage information is available.
>= 5 years old: No maximum dosage information is available.< 5 years old: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit.
Galsulfase should only be administered as an IV infusion.Administration can cause infusion related reactions. Premedication 30—60 minutes prior to the infusion with an antihistamine, with or without antipyretics, is recommended to decrease the incidence of infusion-related reactions. For severe infusion-related reactions, corticosteroids have been used. Carefully monitor the patient during the infusion; have appropriate supportive measures immediately available in the event of a serious allergic reaction.Galsulfase should not be diluted, or infused through the same intravenous line, with other drugs or dextrose solutions.Agitation can denature galsulfase, rendering it inactive. Always use caution to avoid excessive agitation. Do not shake vials or prepared product. Do not use filter needles to prepare the infusion. IV infusion preparation:Determine the number of vials to be used per dose, based on the patient's weight. The dose is 1 mg/kg and each vial contains 5 mg/5 mL, therefore, each patient will receive 1 mL galsulfase per kg; round to the nearest 5 mL to allow for administration of whole vials.Allow the vials to reach room temperature before dilution; do not allow vials to remain at room temperature for more than 24 hours.Prior to withdrawing the solution, visually inspect each vial for particulate matter and discoloration; a few translucent particles may be present. The solution should be clear to slightly opalescent and colorless to pale yellow.The total infusion volume should be 250 mL. Therefore, from a 250 mL infusion bag of 0.9% NaCl, withdraw and discard a volume equal to that of the galsulfase solution to be added. For patients less than 20 kg who are susceptible to fluid overload, physicians may consider diluting galsulfase in 100 mL of 0.9% NaCl. If using a 100 mL bag, withdrawal of the equal volume of galsulfase solution is not necessary.Slowly withdraw galsulfase from the appropriate number of vials, then slowly add to the 0.9% NaCl bag. Gently rotate the infusion bag to ensure distribution of the solution; do not shakeDiluted solutions should be administered immediately. IV infusion administration:Administer over at least 4 hours. The initial infusion rate should be 6 mL/hr for the first hour. If well tolerated, increase the rate to 80 mL/hr for the remaining 3 hours; for patients receiving a 100 mL infusion, the infusion rate should be decreased so that the total infusion time is at least 4 hours. If infusion related reactions occur, the infusion time can be extended to up to 20 hours.Storage: If immediate use is not possible, diluted infusions can be stored in the refrigerator between 2—8 degrees C (36—46 degrees F). Storage after dilution should not exceed 48 hours from the time of preparation to the completion of administration.
Naglazyme:- Protect from freezing- Refrigerate (between 36 and 46 degrees F)
Galsulfase should be used cautiously in patients with hamster protein hypersensitivity (i.e., Chinese hamster ovary cell hypersensitivity), galsulfase hypersensitivity, or hypersensitivity to other components of the product due to increased risk of severe allergic reactions.
Patients with mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome) are at increased risk of infection possibly due to associated cytoplasmic inclusion in polymorphonuclear leukocytes, disease related cranial and other skeletal abnormalities, or decreased pulmonary function. Patients receiving galsulfase have experienced infection related adverse reactions. To avoid complications associated with these infections, it is recommended to delay galsulfase administration to patients with an acute febrile or respiratory infection until the infection has resolved.
Drowsiness associated with antihistamine use, for pretreatment of galsulfase infusion related reactions, can increase the risk of apneic episodes associated with sleep apnea, a common complication seen in MPS VI patients. Evaluation of airway patency should be considered prior to galsulfase administration and patients using supplemental oxygen or continuous positive airway pressure during sleep should have these treatments readily available. Severe infusion related reactions can occur with galsulfase (see Adverse Reactions), thus all patients should receive prophylaxis with an antihistamine with or without antipyretics. Some patients may develop an infusion reaction despite prophylaxis; stopping the infusion and administering additional antihistamines, antipyretics, and occasionally corticosteroids allows for most patients to receive the entire infusion. Subsequent infusions can be managed by slowing the infusion rate, treatment with additional antihistamines, and possibly prophylactic corticosteroids. Even despite these additional measures, 43% of patient have experienced additional infusion related reactions. The risks and benefits of readministering galsulfase after a severe infusion related reaction should be considered.
Patients between the ages of 5—29 years of age (mostly pediatric) were included in clinical studies of galsulfase. The safety and efficacy of galsulfase in neonates, infants and children less than 5 years old have not been established. It is unknown how patients less than 5 years old will react to galsulfase therapy, use cautiously if administering to these patients.
Due to the shortened life span associated with MPS VI, clinical studies did not include patients older than 29 years of age. It is not known if geriatric patients will respond differently to galsulfase compared to younger patients.
There are no available data on galsulfase use during pregnancy to inform a drug-associated risk of pregnancy-related outcomes. Well-controlled studies in pregnant women are lacking; however, animal reproduction studies in rats and rabbits found no effects on embryo-fetal development when galsulfase was given during the period of organogenesis. It is unknown whether galsulfase crosses the human placenta, its molecular weight (about 56,000) and brief half-life suggests minimal if any exposure to the embryo or fetus. Because Maroteaux-Lamy syndrome is a debilitating chronic disease, galsulfase should not be withheld because of pregnancy. There is a pregnancy exposure registry that monitors outcomes in pregnant patients exposed to galsulfase; information about the registry can be obtained at clinicaltrials.gov/ct/show/NCT00214773?order=2.
It is unknown whether galsulfase is excreted in breast milk, however its molecular weight (about 56,000) and brief half-life suggests minimal if any exposure to the nursing infant. In addition, as a glycoprotein, any drug excreted in the milk would most likely be digested in the infant's GI tract. The manufacturer recommends that galsulfase should be used with caution in women who are breast-feeding. A Clinical Surveillance Program is available for lactating women who receive galsulfase. Participation is voluntary and involves long term follow up. Information regarding the program may be obtained by visiting the manufacturer's web site or by calling the US toll free number (800-983-4587). Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.
Cervical or spinal cord compression (SCC) with resultant myelopathy is a known and serious complication of mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). SCC is expected to occur in the natural progression of the disease in spite of treatment with galsulfase. Reports of new onset or worsening SCC requiring decompression surgery have been reported during post marketing surveillance of galsulfase. Patients with MPS VI should be monitored for signs and symptoms of cervical/spinal cord compression (including back pain, paralysis of limbs below the level of compression, urinary and fecal incontinence) and given appropriate clinical care.
corneal opacification / Delayed / 11.0-11.0hearing loss / Delayed / 11.0-11.0cyanosis / Early / Incidence not knownangioedema / Rapid / Incidence not knownbradycardia / Rapid / Incidence not knownapnea / Delayed / Incidence not knownglomerulonephritis / Delayed / Incidence not knownlaryngeal edema / Rapid / Incidence not knownanaphylactoid reactions / Rapid / Incidence not knownanaphylactic shock / Rapid / Incidence not knownbronchospasm / Rapid / Incidence not knownspinal cord compression / Delayed / Incidence not known
antibody formation / Delayed / 98.0-98.0infusion-related reactions / Rapid / 56.0-56.0dyspnea / Early / 21.0-21.0conjunctivitis / Delayed / 21.0-21.0chest pain (unspecified) / Early / 16.0-16.0hypertension / Early / 11.0-11.0sinus tachycardia / Rapid / Incidence not knownhypoxia / Early / Incidence not knownerythema / Early / Incidence not knowntachypnea / Early / Incidence not knownhypotension / Rapid / Incidence not knownthrombocytopenia / Delayed / Incidence not known
abdominal pain / Early / 47.0-47.0arthralgia / Delayed / 42.0-42.0otalgia / Early / 42.0-42.0chills / Rapid / 21.0-21.0rash / Early / 21.0-21.0malaise / Early / 11.0-11.0hyporeflexia / Delayed / 11.0-11.0nasal congestion / Early / 11.0-11.0pharyngitis / Delayed / 11.0-11.0nausea / Early / Incidence not knownpallor / Early / Incidence not knownurticaria / Rapid / Incidence not knownheadache / Early / Incidence not knownparesthesias / Delayed / Incidence not knownfever / Early / Incidence not knownshivering / Rapid / Incidence not knownvomiting / Early / Incidence not knowninfection / Delayed / Incidence not knowncough / Delayed / Incidence not knowndiarrhea / Early / Incidence not known
Gentamicin: (Minor) There is a possible drug interaction between galsulfase and medications which may impact lysosomal efficacy. Gentamicin slightly increases the intralysosomal pH of proximal tubular cells and decreases the activity of the lysosomal proteinases, cathepsin B and L, which are proteolytic activators of other lysosomal enzymes. Because similar interactions have occurred between gentamicin and other therapies used for a similar disease, the effectiveness of galsulfase therapy should be monitored during coadministration.
Galsulfase is taken up into cellular lysosomes through the binding of manose-6 phosphate-terminated oligosaccharide chains of galsulfase to specific cellular mannosephosphate receptors. Once incorporated into cellular lysosomes, it increases the catabolism of glycosaminoglycans (GAGs). Galsulfase replaces the enzyme N-acetylgalactosamine 4-sulfatase, which is a lysosomal hydrolase that catalyses the cleavage of the sulfate ester from terminal N-acetylgalactosamine 4-sulfatase residues of the GAGs chondroitin 4-sulfate and dermatan sulfate. The accumulation of dermatan sulfate throughout the body results in the manifestations of the disease mucopolysaccharidosis VI; galsulfase is administered to promote catabolism, and prevent further accumulation, of dermatan sulfate and relieve the symptoms of this disease.
Galsulfase is administered via intravenous infusion. Following 24 weeks of treatment in patients with mucopolysaccharidosis VI, at a dose of 1 mg/kg per week, specific pharmacokinetic parameters of galsulfase were reported: median clearance was 3.7 mL/kg/min (range 1.1—55.9 mL/kg/min); and median half life was 26 minutes (range 8—40 minutes). Urinary glycosaminoglycan (GAG) concentrations decreased over 24 weeks of treatment, although normal urinary GAG concentrations were not achieved. It appears that reduction of urinary GAG is dose dependent. Another study has shown that reductions in urinary GAG concentrations have been maintained for over 2.5 years; it has been suggested that urinary GAG levels below 100 mg/mg creatinine are associated with improved mortality. It is unclear if the development of anti-galsulfase antibodies affects the efficacy of galsulfase. The assessment of antibodies from one patient showed evidence of in vitro inhibition of galsulfase activity. Unfortunately, other patients' antibodies were not tested for neutralizing effect. However, the comparison of antibody test results may be misleading due to possible differences in assay sensitivity and specificity.
Following 24 weeks of treatment in patients with mucopolysaccharidosis VI, at a dose of 1 mg/kg per week, specific pharmacokinetic parameters of galsulfase were reported: median peak plasma concentration was 1.5 mcg/mL (range 0.2—5.5 mcg/mL) and median AUC was 4.3 h x mcg/mL (range 1—3.5 h x mcg/mL). Overall, 98% of patients who received galsulfase in clinical trials developed anti-galsulfase IgG antibodies within 4 to 8 weeks of treatment. After 24 weeks of treatment, high antibody titers were associated with a decrease in galsulfase plasma AUC in 4 patients and an increase in galsulfase plasma AUC in 1 patient.